The material on this site is directed only at persons resident in Switzerland, France, Liechtenstein and the UK.

The following information and documents do not constitute a solicitation or offer, or recommendation to buy or sell Novartis shares, to effect any transactions, to conclude any legal act of any kind whatsoever, or to subscribe to services made to persons residing in jurisdictions where such solicitation, offer or recommendation requires a local license.

The following information and documents are not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the publication or availability of the Novartis Webpage is prohibited. Persons in respect of whom such prohibitions apply must not access the following information and documents.

The Direct Share Purchase Plan is open to shareholders and investors residing in Switzerland, France, Liechtenstein and UK. Due to legal restrictions, investors residing outside Switzerland, France, Liechtenstein or UK may not download the documents related to the Direct Share Purchase Plan and/or access further information on the Direct Share Purchase Plan.

The Direct Share Purchase Plan is regulated by Swiss Law.

Notice to UK residents: Novartis is in material compliance with all applicable provisions of the UK’s Financial Services and Markets Act 2000 (including secondary legislation thereunder), the FSA’s Handbook of Rules and Guidance, the Data Protection Act 1998 and other equivalent data protection legislation applicable in Member States of the EEA.

Notice to French residents: When printing out the available subscription documentation and returning it duly completed to us, you acknowledge that you have not been the subject, neither on our part nor on our behalf, of any active solicitation act carried out in your jurisdiction which would trigger licensing requirements in your jurisdiction.

We draw your attention to the fact that Novartis is not licensed to provide custody or brokerage services in France. Accordingly, in case of default or bankruptcy of Novartis, you will not benefit from the indemnification scheme provided for under Articles L 322-1 to L 322-4 of the French Monetary and Financial Code.

I agree ›